Scripscan:Parabolic Drugs Ltd
Code:533211
Cmp:40
Story:Parabolic Drugs Limited engages in the manufacture and contract manufacture of active pharmaceutical ingredients (API) and API intermediates. The company offers semi synthetic penicillin and cephalosporin range of antibiotics in oral and sterile forms, as well as provides Ceftazidime, Cefotiam, Ceftizoxime, and Cephalothin. It serves pharmaceutical companies in South East Asia, North America, Latin America, Brazil, the Middle East, North Africa, and parts of East and South Africa.It has two manufacturing facilities located at Derabassi, Punjab and Panchkula, Haryana.The company has also started the operations at its custom synthesis and R&D centre at Barwala, Haryana from January 2010.The name, business and logo of ‘Parabolic’ are not registered trademarks of the company. This can place the company at a disadvantage in respect of Intellectual Property rights.Its unfavourable capital structure, project stabilization risk, volatility in prices of imported raw material along-with exposure to exchange risk on account of imports and liabilities denominated in foreign currency,are some risks which can concern an investor.However the company has performed exceptionally well in the last 5 years and management has indicated strong robust future growth.Experienced management, approvals and certificates of suitability for few products from regulatory authorities in the US,EU and other regulated markets, reputed client base,strong focus on R&D activities and the company's strategy to diversify into CRAMS business gives some conviction.At 40rs its a hold.
Subscribe to:
Post Comments (Atom)
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
No comments:
Post a Comment